# OnCo record paper-glofitamab-dlbcl-lancet-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-glofitamab-dlbcl-lancet-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-glofitamab-dlbcl-lancet-2024" ;
  schema:name "Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial"@en ;
  schema:description "Phase 2 or 3 results paper on Glofitamab in Diffuse large B-cell lymphoma, in The Lancet (2024), one of the most cited Europe PMC records with Glofitamab in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-glofitamab-dlbcl-lancet-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(24)01774-4>, <https://pubmed.ncbi.nlm.nih.gov/39550172/>, <https://europepmc.org/article/MED/39550172>, <https://clinicaltrials.gov/study/NCT04408638> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(24)01774-4> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Abramson JS, Ku M, Hertzberg M, et al." ;
  onco:trials <https://onco.cc/trials/starglo/> ;
  onco:journals <https://onco.cc/journals/lancet/> .